Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.34 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139202 | 0.91 | DHODH (0.35) | DHODH | |
| SCHEMBL4125426 | 0.91 | HTR2A (0.37) | HTR6HTR2AHTR2CHTR7DHODH | |
| SCHEMBL3648852 | 0.89 | NFE2L2 (0.39) | NFE2L2 | |
| SCHEMBL4131238 | 0.88 | NAMPT (0.37) | HTR2C | |
| SCHEMBL4118448 | 0.87 | DHODH (0.33) | DHODH | |
| SCHEMBL3655779 | 0.86 | PDE4A (0.40) | — | |
| SCHEMBL3649570 | 0.84 | HTR6 (0.34) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL4125986 | 0.84 | ALDH1A1 (0.40) | DHODH | |
| SCHEMBL3649326 | 0.83 | HTR6 (0.39) | HTR6HTR2AHTR2CHTR7NFE2L2 | |
| SCHEMBL3649572 | 0.83 | HTR6 (0.33) | HTR6HTR2AHTR2CHTR7DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | HTR6 3676/4885HTR2A 3643/4885HTR2C 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.